Fierce Pharma

JUNE 29, 2023

While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.

Vaccines 77

Vaccines Immunization 77

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunization 80

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

Vaccines 111

Vaccines Immunization FDA 111

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

JUNE 15, 2022

Cytokines have long been investigated for their potential as cancer treatments – selectively stimulate tumour-fighting immune cells – with varying levels of success. Trutino’s lead in-house asset is in early-stage development and scheduled to start clinical testing in solid tumours in 2025.

Immunization 98

Immunization Vaccines 98

PQA

MARCH 28, 2025

We also highlight our members' perspectives on pharmacy interoperability, immunizations and nutrition. Authors of the report believe removing these protocols and giving more authority to pharmacists would significantly improve immunization rates among U.S. Learn morebelow. Of note, PQA is conducting an immunizationpilot.

Health and Personal Care Stores 52

Health and Personal Care Stores Immunization Vaccines 52

PQA

NOVEMBER 1, 2024

We also highlight our members' perspectives on health outcomes, oral oncolytics and vaccination recommendations. In a second session, he reviewed the latest updates on vaccines for meningococcal disease, human papillomavirus, and tetanus, diphtheria, and pertussis, among others. Learn more about the summit and PQA Convenes t below.

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. Demolition of the existing buildings on the site will commence next year, and construction work on the new building will begin in 2025.

Immunization 52

Immunization Vaccines 52

pharmaphorum

OCTOBER 12, 2022

Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Immunization 105

Immunization Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Vaccines 52

Vaccines Packaging Immunization FDA 52

Hospital Pharmacy Europe

JUNE 27, 2024

Amidst the spotlight on vaccine development, therapeutic interventions remained a critical, yet often overlooked, aspect of pandemic preparedness. While a new set of international health regulations were agreed at the Assembly, the timeline for the terms of the pandemic accord was extended to the next meeting in 2025.

Vaccines 52

Vaccines Compounding Immunization Hospitals 52

Hospital Pharmacy Europe

JUNE 27, 2024

Amidst the spotlight on vaccine development, therapeutic interventions remained a critical, yet often overlooked, aspect of pandemic preparedness. While a new set of international health regulations were agreed at the Assembly, the timeline for the terms of the pandemic accord was extended to the next meeting in 2025.

Vaccines 52

Vaccines Compounding Immunization Hospitals 52

DiversifyRx

DECEMBER 11, 2024

What’s the secret sauce to growing your pharmacy in 2025? Gain 50 new flu vaccine patients in January. Identify Key Areas of Focus: Think about the services or products you want to promote, such as weight loss programs, immunizations, or non-PBM revenue streams. Ready to make 2025 your best year yet?

Vaccines 52

Vaccines Immunization Independent Pharmacies 52

The Checkup by Singlecare

SEPTEMBER 10, 2024

There have been several biosimilars approved, including Wezlana , Selarsdi, and Pyzchiva, but they are not expected to be available until early 2025. But Stelara is a biologic product , meaning it will have what’s called a biosimilar instead of a generic version. Continue reading to learn more about Stelara and its biosimilars.

FDA 52

FDA Vaccines Specialty Pharmacies Pharmaceutical Companies 52

The Checkup by Singlecare

JUNE 7, 2024

It works on proteins that affect the immune system, which helps improve symptoms such as inflammation. As an immunosuppressive medicine, Stelara affects the immune system, which increases the risk of infections, including serious infections that require hospitalization. Made by the pharmaceutical company Janssen Biotech, Inc.,

Immunization 52

Immunization Dosage Vaccines FDA 52

PharmaShots

JUNE 1, 2023

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients.

Immunization 40

Immunization Vaccines Health and Personal Care Stores Labelling 40

pharmaphorum

JANUARY 13, 2023

Everyone agrees that cell and gene therapies are poised for an explosion, with far more drugs in the pipeline than are currently approved, and the FDA predicts it will clear 10 to 20 per year by 2025. These therapies have incredible potential to fight cancer and other diseases using the patient’s own immune system.

FDA 98

FDA Immunization Vaccines 98

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

MAY 23, 2023

Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. It has triple mutation within the viral genome that causes augmented and selective replication in cancer cells and enhances induction of antitumor immune response.

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

The FDA Law Blog

AUGUST 14, 2022

Medicare Part D redesign: The IRA changes Medicare Part D starting in 2025 by lowering the patient out-of-pocket (“OOP”) limit to $2,000, adjusted annually in subsequent years. The same will be required under state Medicaid and CHIP programs by October 1, 2023.

Vaccines 98

Vaccines Immunization 98

STAT

MARCH 21, 2025

In 2000, after decades of hard work and widespread vaccination campaigns, public health officials declared measles eliminated in the U.S. Fueled by growing mistrust in vaccine science and years of small but meaningful declines in routine childhood vaccinations, measles has made a troubling comeback. Read the rest…

Vaccines 142

Vaccines Documentation Immunization 142

European Pharmaceutical Review

FEBRUARY 3, 2025

EMAs human medicines committee (CHMP) recommended eight medicines for EU marketing authorisation at its January 2025 meeting. New vaccine Vimkunya (chikungunya vaccine (recombinant, adsorbed)) was also recommended for individuals 12 years old and adults to prevent disease caused by the Chikungunya virus.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Immunization 52

BuzzRx

AUGUST 30, 2022

Then, in 2025 the law will add a $2,000 cap on spending. Cost sharing for adult vaccines covered by Medicare Part D will be eliminated In 2020, more than 4 million Medicare beneficiaries received a vaccine covered under Part D, including 3.6 million who received the shingles vaccine.

Vaccines 52

Vaccines Insurance Packaging Immunization 52